JP2022166140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022166140A5 JP2022166140A5 JP2022127059A JP2022127059A JP2022166140A5 JP 2022166140 A5 JP2022166140 A5 JP 2022166140A5 JP 2022127059 A JP2022127059 A JP 2022127059A JP 2022127059 A JP2022127059 A JP 2022127059A JP 2022166140 A5 JP2022166140 A5 JP 2022166140A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cancer
- domain
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 10
- 230000008685 targeting Effects 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108010079723 Shiga Toxin Proteins 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102000008102 Ankyrins Human genes 0.000 claims 1
- 108010049777 Ankyrins Proteins 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000002086 C-type lectin-like Human genes 0.000 claims 1
- 108050009406 C-type lectin-like Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- -1 Kunitz domain Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 101000844753 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) DNA-binding protein 7d Proteins 0.000 claims 1
- 102100038126 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000003437 pleural cancer Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 description 1
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 description 1
- 108010030685 KDEL receptor Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
Description
カルボキシ末端リジン-アスパラギン-グルタメート-ロイシン(KDEL)配列(配列番号:60)は、真核生物細胞内の可溶性タンパク質のカノニカル小胞体残留及び回収シグナルモチーフであり、KDEL受容体によって認識される(Capitani M, Sallese M, FEBS Lett 583: 3863-71 (2009)を参照されたい)。シグナルモチーフのKDELファミリーは、多くのKDEL様モチーフ、例えば、HDEL(配列番号:62)、RDEL(配列番号:64)、WDEL(配列番号:65)、YDEL(配列番号:66)、HEEL(配列番号:68)、KEEL(配列番号:69)、REEL(配列番号:70)、KFEL(配列番号:73)、KIEL(配列番号:85)、DKEL(配列番号:86)、KKEL(配列番号:89)、HNEL(配列番号:93)、HTEL(配列番号:94)、KTEL(配列番号:95)及びHVEL(配列番号:96)を含み、これらの全てが、系統発生学上の複数の界にわたって小胞体の内腔の常在物であることが公知であるタンパク質のカルボキシ末端において見出される(Munro S, Pelham H, Cell 48: 899-907 (1987)、RaykhelIet al., JCell Biol 179: 1193-204 (2007))。KDELシグナルモチーフファミリーは、合成構築物を使用して証明された少なくとも46のポリペプチドバリアントを含む(Raykhel, J Cell Biol 179: 1193-204(2007))。さらなるKDELシグナルモチーフは、ALEDEL(配列番号:106)、HAEDEL(配列番号:107)、HLEDEL(配列番号:108)、KLEDEL(配列番号:109)、IRSDEL(配列番号:110)、ERSTEL(配列番号:111)、及びRPSTEL(配列番号:112)を含む(Alanen H et al., JMol Biol 409: 291-7 (2011))。大部分のKDELシグナルモチーフを表す一般化コンセンサスモチーフは、[KRHQSA]-[DENQ]-E-L(配列番号:137)と記載されている(Hulo N et al., NucleicAcids Res 34: D227-30(2006))。
Claims (15)
- 細胞標的化分子であって、
i)細胞の表面に物理的に結合している細胞外標的生体分子に特異的に結合することができる結合領域であって、前記細胞外標的生体分子がHER2/neu/ErbB2、CD38、CD20、CTLA-4、BCMA又はSLAMF7である、前記結合領域と、
ii)配列番号1のアミノ酸1~251に対して少なくとも90%の同一性を有するアミノ酸配列を含む志賀毒素エフェクターポリペプチドであって、前記アミノ酸配列が、配列番号1のS45からIへのアミノ酸置換、配列番号1のR55からLへのアミノ酸置換、配列番号1のI57からFへのアミノ酸置換、配列番号1のP59からFへのアミノ酸置換、配列番号1のE60からTへのアミノ酸置換、配列番号1のE61からLへのアミノ酸置換、配列番号1のG110からAへのアミノ酸置換、配列番号1のR188からAへのアミノ酸置換、配列番号1のC242からSへのアミノ酸置換、配列番号1のR248からAへのアミノ酸置換、及び配列番号1のR251からAへのアミノ酸置換を含み、かつ、前記アミノ酸配列が、
配列番号1の75位に対応するアミノ酸残基でアスパラギン、
配列番号1の77位に対応するアミノ酸残基でチロシン、
配列番号1の114位に対応するアミノ酸残基でチロシン、
配列番号1の167位に対応するアミノ酸残基でグルタメート、
配列番号1の170位に対応するアミノ酸残基でアルギニン、
配列番号1の176位に対応するアミノ酸残基でアルギニン、及び
配列番号1の203位に対応するアミノ酸残基でトリプトファン
を含む、前記志賀毒素エフェクターポリペプチドと
を含む、前記細胞標的化分子。 - 志賀毒素エフェクターポリペプチドが、配列番号1のアミノ酸1~251に対して少なくとも95%の配列同一性を有するアミノ酸配列を含む、請求項1に記載の細胞標的化分子。
- 結合領域が、志賀毒素エフェクターポリペプチドのカルボキシ末端に融合され、単一の連続的なポリペプチドを形成する、請求項1又は2に記載の細胞標的化分子。
- 結合領域が、免疫グロブリン型結合領域を含む、請求項1~3のいずれかに記載の細胞標的化分子。
- 免疫グロブリン型結合領域が、
シングルドメイン抗体断片、一本鎖可変断片、抗体可変断片、相補性決定領域3断片、拘束FR3-CDR3-FR4ポリペプチド、Fd断片、抗原結合断片、フィブロネクチン由来第10フィブロネクチンIII型ドメイン、テネイシンIII型ドメイン、アンキリン反復モチーフドメイン、低密度リポタンパク質受容体由来Aドメイン、リポカリン、Kunitzドメイン、プロテインA由来Zドメイン、ガンマ-B結晶由来ドメイン、ユビキチン由来ドメイン、Sac7d由来ポリペプチド、Fyn由来SH2ドメイン、ミニタンパク質、C型レクチン様ドメイン足場、ラクダ科動物VHH断片に由来する重鎖抗体ドメイン、軟骨魚類に由来する重鎖抗体ドメイン、免疫グロブリン新規抗原受容体(IgNAR)、VNAR断片、多量体化scFv断片(ダイアボディ、トリアボディ、テトラボディ)、二価ナノボディ、二重特異性タンデムscFv、及び二重特異性ミニボディ
から選択されるポリペプチドを含む、請求項4に記載の細胞標的化分子。 - リンカーペプチド(GxS)n(配列番号115)(式中xが1~6であり、nが1~30である)を含む、請求項1~5のいずれかに記載の細胞標的化分子。
- xが4であり、nが1である、請求項6に記載の細胞標的化分子。
- 請求項1~7のいずれかに記載の細胞標的化分子と、薬学的に許容される賦形剤又は担体とを含む医薬組成物。
- 請求項1~7のいずれかに記載の細胞標的化分子をコードするポリヌクレオチド、又はその相補体。
- 請求項9に記載のポリヌクレオチドを含む発現ベクター。
- 請求項9に記載のポリヌクレオチド又は請求項10に記載の発現ベクターを含む、宿主細胞。
- 請求項1~7のいずれかに記載の細胞標的化分子又は請求項8に記載の医薬組成物を含む、患者の疾患、障害又は状態の治療剤。
- 疾患、障害又は状態が、がん、腫瘍、増殖異常、免疫障害及び微生物感染から選択される、請求項12に記載の治療剤。
- がんが、骨がん、乳がん、中枢/末梢神経系がん、胃腸がん、胚細胞がん、腺がん、頭頸部がん、血液がん、腎・尿路癌、肝がん、肺/胸膜がん、前立腺がん、肉腫、皮膚がん及び子宮がんから選択される、請求項13に記載の治療剤。
- 免疫障害が、アミロイドーシス、強直性脊椎炎、喘息、クローン病、糖尿病、移植片拒絶、移植片対宿主病、橋本甲状腺炎、溶血性尿毒症症候群、HIV関連疾患、全身性エリテマトーデス、多発性硬化症、多発動脈炎、乾癬、乾癬性関節炎、リウマチ様関節炎、強皮症、敗血症性ショック、シェーグレン症候群、潰瘍性大腸炎、及び血管炎から選択される疾患に関連する、請求項13に記載の治療剤。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461932000P | 2014-01-27 | 2014-01-27 | |
US61/932,000 | 2014-01-27 | ||
US201462049325P | 2014-09-11 | 2014-09-11 | |
US62/049,325 | 2014-09-11 | ||
JP2020002993A JP2020073569A (ja) | 2014-01-27 | 2020-01-10 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2021102325A JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021102325A Division JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022166140A JP2022166140A (ja) | 2022-11-01 |
JP2022166140A5 true JP2022166140A5 (ja) | 2022-11-09 |
JP7402556B2 JP7402556B2 (ja) | 2023-12-21 |
Family
ID=52469328
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016546493A Active JP6646584B2 (ja) | 2014-01-27 | 2015-01-26 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2016546476A Active JP6655017B2 (ja) | 2014-01-27 | 2015-01-26 | Mhcクラスiエピトープ送達ポリペプチド |
JP2020002993A Pending JP2020073569A (ja) | 2014-01-27 | 2020-01-10 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2020014954A Pending JP2020079267A (ja) | 2014-01-27 | 2020-01-31 | Mhcクラスiエピトープ送達ポリペプチド |
JP2021092504A Active JP7229570B2 (ja) | 2014-01-27 | 2021-06-01 | Mhcクラスiエピトープ送達ポリペプチド |
JP2021102325A Active JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2022127059A Active JP7402556B2 (ja) | 2014-01-27 | 2022-08-09 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2023016832A Active JP7442879B2 (ja) | 2014-01-27 | 2023-02-07 | Mhcクラスiエピトープ送達ポリペプチド |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016546493A Active JP6646584B2 (ja) | 2014-01-27 | 2015-01-26 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2016546476A Active JP6655017B2 (ja) | 2014-01-27 | 2015-01-26 | Mhcクラスiエピトープ送達ポリペプチド |
JP2020002993A Pending JP2020073569A (ja) | 2014-01-27 | 2020-01-10 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
JP2020014954A Pending JP2020079267A (ja) | 2014-01-27 | 2020-01-31 | Mhcクラスiエピトープ送達ポリペプチド |
JP2021092504A Active JP7229570B2 (ja) | 2014-01-27 | 2021-06-01 | Mhcクラスiエピトープ送達ポリペプチド |
JP2021102325A Active JP7126729B2 (ja) | 2014-01-27 | 2021-06-21 | 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023016832A Active JP7442879B2 (ja) | 2014-01-27 | 2023-02-07 | Mhcクラスiエピトープ送達ポリペプチド |
Country Status (12)
Country | Link |
---|---|
US (6) | US20160347798A1 (ja) |
EP (4) | EP3099705B1 (ja) |
JP (8) | JP6646584B2 (ja) |
KR (6) | KR20230028808A (ja) |
CN (4) | CN111909278B (ja) |
AU (8) | AU2015209065C1 (ja) |
CA (2) | CA2937407A1 (ja) |
ES (2) | ES2877356T3 (ja) |
HK (2) | HK1226083A1 (ja) |
IL (8) | IL302552B1 (ja) |
MX (4) | MX2016009807A (ja) |
WO (2) | WO2015113005A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
AU2011302645B2 (en) | 2010-09-15 | 2015-02-26 | Applied Molecular Transport, Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
LT2970487T (lt) | 2013-03-12 | 2020-05-11 | Molecular Templates, Inc. | Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui |
EP3524263A1 (en) | 2013-03-28 | 2019-08-14 | Invectys | A cancer vaccine for dogs |
EP3449936A1 (en) | 2013-03-28 | 2019-03-06 | Invectys | A cancer vaccine for cats |
PL3062824T3 (pl) * | 2013-10-28 | 2020-06-15 | Invectys | Szczepionka zawierająca dna kodujący telomerazę |
ES2753412T3 (es) | 2013-10-28 | 2020-04-08 | Invectys | Electrotransferencia génica a las células de la piel |
ES2877356T3 (es) | 2014-01-27 | 2021-11-16 | Molecular Templates Inc | Epítopo de MHC de clase I que suministra polipéptidos |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
ES2723774T3 (es) * | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
AU2015255834B2 (en) | 2014-05-07 | 2020-05-21 | Applied Molecular Transport Llc | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
CN106604934A (zh) | 2014-06-11 | 2017-04-26 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
AU2016215205B2 (en) | 2015-02-05 | 2021-10-21 | Molecular Templates, Inc. | Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
EP3660035A1 (en) * | 2015-05-30 | 2020-06-03 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
KR20180030085A (ko) | 2015-07-26 | 2018-03-21 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
KR20180055899A (ko) * | 2015-10-02 | 2018-05-25 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 탈면역화된 치료 조성물 및 방법 |
KR20180107102A (ko) * | 2015-12-16 | 2018-10-01 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원 동정, 제조, 및 용도 |
KR102325611B1 (ko) * | 2016-05-09 | 2021-11-12 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 실온 경화성 오르가노폴리실록산 조성물의 경화물로 코팅된 수중 구조물, 수중 구조물 코팅용의 실온 경화성 오르가노폴리실록산 조성물 및 수중 구조물 표면으로의 수생 생물의 부착·생육을 방지하는 방법 |
KR102580647B1 (ko) | 2016-12-07 | 2023-09-20 | 몰레큘러 템플레이츠, 인코퍼레이션. | 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자 |
CN110536695B (zh) | 2017-01-25 | 2024-05-10 | 分子模板公司 | 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子 |
US20220193129A1 (en) * | 2017-04-27 | 2022-06-23 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents and dosages thereof |
WO2018206512A1 (en) | 2017-05-09 | 2018-11-15 | Invectys | Recombinant measles vaccine expressing htert |
CN111465989A (zh) | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | 使用热点进行的新抗原鉴别 |
EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
AU2019211121A1 (en) * | 2018-01-26 | 2020-08-27 | Cambridge Enterprise Limited | Peptide exchange protein |
ES2920428T3 (es) | 2018-03-08 | 2022-08-03 | Applied Molecular Transport Inc | Constructos de administración derivados de toxinas para la administración oral |
JP7323200B2 (ja) | 2018-04-17 | 2023-08-08 | モレキュラー テンプレーツ,インク. | 脱免疫化志賀毒素aサブユニット足場を含むher2ターゲティング分子 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
CN109504683A (zh) * | 2018-11-13 | 2019-03-22 | 广西壮族自治区水产科学研究院 | 罗非鱼的半乳糖凝集素-3基因序列及其克隆方法 |
WO2020154531A1 (en) | 2019-01-23 | 2020-07-30 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
GB201910605D0 (en) * | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
AU2020348861A1 (en) | 2019-09-18 | 2022-01-27 | Molecular Templates, Inc. | PD-L1 binding molecules comprising Shiga toxin A Subunit scaffolds |
US20210155671A1 (en) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Uses of cd20-binding molecules and additional therapeutic agents |
CN113621030B (zh) * | 2020-07-14 | 2023-05-26 | 上海科技大学 | 一种诱导蛋白质降解的多肽及其应用 |
US20220195050A1 (en) | 2020-12-16 | 2022-06-23 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
EP4308242A1 (en) | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
WO2023172983A1 (en) * | 2022-03-08 | 2023-09-14 | Molecular Templates, Inc. | Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof |
CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080898A (en) | 1982-05-12 | 1992-01-14 | The University Hospital | Enzymatically active toxin coupled to a cell-specific ligand |
US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
AU657087B2 (en) | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
US5635384A (en) | 1990-06-11 | 1997-06-03 | Dowelanco | Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using |
US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
US5552144A (en) | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
AU6912294A (en) | 1993-05-12 | 1994-12-12 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
CA2218601A1 (en) | 1995-03-24 | 1996-10-03 | Ophidian Pharmaceuticals, Inc. | Treatment for verotoxin-producing escherichia coli |
US5667786A (en) * | 1995-06-07 | 1997-09-16 | Novavax, Inc. | Method for treating tumors with a toxin |
US5858682A (en) | 1996-08-02 | 1999-01-12 | Pharmingen | E2A/pbx1 fusion protein specific monoclonal antibodies |
PT929567E (pt) | 1996-09-09 | 2005-07-29 | Zealand Pharma As | Sintese em fase solida de peptidos |
JP2001500730A (ja) | 1996-09-10 | 2001-01-23 | ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン | ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法 |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
FR2766193B1 (fr) | 1997-07-18 | 2001-09-14 | Inst Curie | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique |
CA2222993A1 (en) | 1998-02-04 | 1999-08-04 | The Ontario Cancer Institute | A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries |
JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、cd38に対する、遺伝子操作した抗体の使用 |
DK1098664T3 (da) | 1998-07-22 | 2003-11-17 | Osprey Pharmaceuticals Ltd | Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US6492498B1 (en) | 1999-11-15 | 2002-12-10 | Regents Of The University Of Minnesota | Multimeric immunotoxins |
US20010031485A1 (en) * | 2000-03-22 | 2001-10-18 | Sibtech, Inc. | Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments |
US7267973B2 (en) | 2000-03-22 | 2007-09-11 | Sibtech, Inc. | Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
JP4214397B2 (ja) | 2002-02-04 | 2009-01-28 | 秀男 吉田 | 変異ベロ毒素を用いた抗癌剤 |
US20050239043A1 (en) | 2002-02-26 | 2005-10-27 | Harding Fiona A | Subtilisin carlsberg proteins with reduced immunogenicity |
CN1649902B (zh) | 2002-03-01 | 2011-04-13 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
AU2003303374A1 (en) | 2002-12-20 | 2004-07-22 | The Johns Hopkins University | Treatment of metastatic cancer with the b-subunit of shiga toxin |
WO2005000902A1 (en) | 2003-06-30 | 2005-01-06 | Mu-Hyeon Choe | The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
ES2343965T3 (es) | 2003-11-25 | 2010-08-13 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Anticuerpos anti-cd22 e inmunocongujados mutados. |
WO2005052129A2 (en) | 2003-11-25 | 2005-06-09 | Anjin Corporation | Diptheria toxin variant |
MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
WO2005092917A1 (en) | 2004-03-26 | 2005-10-06 | Jean Gariepy | Library of toxin mutants, and methods of using same |
US8858930B2 (en) * | 2004-10-26 | 2014-10-14 | Chengru Zhu | Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic Escherichia coli in cattle |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
FI20055417A0 (fi) | 2005-07-20 | 2005-07-20 | Glykos Finland Oy | Syöpäpesifiset glykaanit ja niiden käyttö |
AU2006272597A1 (en) | 2005-07-25 | 2007-02-01 | Emergent Product Development Seattle Llc | Single dose use of CD20-specific binding molecules |
EP2402367A1 (en) | 2005-09-26 | 2012-01-04 | Molecular Templates, Inc. | Library from toxin mutants, and methods of using same |
GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
US9109223B2 (en) | 2005-12-23 | 2015-08-18 | Viventia Bio, Inc. | Methods for generating and screening fusion protein libraries and uses thereof |
WO2007098201A2 (en) | 2006-02-16 | 2007-08-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Shiga toxoid chimeric proteins |
US7373982B2 (en) | 2006-03-21 | 2008-05-20 | Halliburton Energy Services, Inc. | Cements for use across formations containing gas hydrates |
CN101622352A (zh) * | 2006-12-29 | 2010-01-06 | 美国奥斯普瑞医药公司 | 选择和产生修饰的毒素、含有修饰的毒素的缀合物的方法及其应用 |
CA2673668A1 (en) | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
GB2456904B8 (en) * | 2007-03-22 | 2009-12-09 | Heptares Therapeutics Ltd | Stable neurotensin receptor mutants |
WO2008157776A2 (en) | 2007-06-21 | 2008-12-24 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
US7887801B2 (en) | 2007-07-13 | 2011-02-15 | Topotarget Germany Ag | Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
CA2695382A1 (en) | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
US8871906B2 (en) | 2007-09-04 | 2014-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes |
WO2009088403A2 (en) | 2007-10-08 | 2009-07-16 | Rutgers, The State University | Nontoxic shiga-like toxin mutant compositions and methods |
EP2048896B1 (en) | 2007-10-12 | 2011-12-21 | STMicroelectronics Srl | Method and circuit for testing an audio high-frequency loudspeaker being part of a loudspeaker system |
US20090148904A1 (en) | 2007-11-13 | 2009-06-11 | Mayfield Stephen P | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
BRPI0819656A2 (pt) | 2007-11-27 | 2015-06-23 | Ablynx Nv | Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas |
WO2009078766A1 (en) | 2007-12-17 | 2009-06-25 | Telefonaktiebolaget Lm Ericsson (Publ) | Multi-antenna receiver interference cancellation method and apparatus |
EP2268297A4 (en) * | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | MODIFIED TOXINS |
CN101629158A (zh) * | 2008-07-17 | 2010-01-20 | 冯书章 | 出血性大肠杆菌o157重组疫苗 |
NZ590330A (en) | 2008-07-21 | 2012-08-31 | Immunomedics Inc | Structural variants of anti-cd20 antibodies for improved therapeutic characteristics |
AU2009293640A1 (en) | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods and vectors for display of 2G12 -derived domain exchanged antibodies |
WO2010046778A2 (en) * | 2008-10-21 | 2010-04-29 | International Vaccine Institute | Novel shigella frotein antigens and methods |
CN102292098A (zh) * | 2009-01-23 | 2011-12-21 | 杰克孙M.亨利基金会先进军事医学有限公司 | 基于志贺毒素2型蛋白的方法和组合物 |
AU2010240569A1 (en) | 2009-04-20 | 2011-10-20 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
US20120258104A1 (en) | 2009-07-22 | 2012-10-11 | Cenix Bioscience Gmbh | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes |
CN102575542B (zh) | 2009-08-14 | 2014-09-10 | 尤尼弗瑞克斯I有限责任公司 | 用于排气处理装置的安装垫 |
EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
CN103154035B (zh) | 2010-05-27 | 2017-05-10 | 根马布股份公司 | 针对her2的单克隆抗体 |
GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
PL219845B1 (pl) | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
EP2476441A1 (en) * | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
WO2012101235A1 (en) | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
JP6261341B2 (ja) | 2011-02-01 | 2018-01-17 | ゲンマブ エー/エス | Cd74に対するヒト抗体および抗体−薬物コンジュゲート |
US20140088019A1 (en) * | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
US8895006B2 (en) * | 2011-03-04 | 2014-11-25 | Rutgers, The State University Of New Jersey | Ricin ribosome binding protein compositions and methods of use thereof |
BR112013028537A2 (pt) | 2011-05-06 | 2017-01-17 | Us Gov Health & Human Serv | imunotoxina recombinante que visa a mesotelina |
PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
WO2013126690A1 (en) | 2012-02-23 | 2013-08-29 | President And Fellows Of Harvard College | Modified microbial toxin receptor for delivering agents into cells |
JP2014021782A (ja) | 2012-07-19 | 2014-02-03 | Canon Inc | 画像処理装置、その制御方法及びプログラム |
EP2740493A1 (en) | 2012-12-05 | 2014-06-11 | Institut Curie | Conjugates of the B-subunit of Shiga toxin for anticancer therapies |
LT2970487T (lt) | 2013-03-12 | 2020-05-11 | Molecular Templates, Inc. | Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui |
EP2778173A1 (en) | 2013-03-15 | 2014-09-17 | Laboratoire Français du Fractionnement et des Biotechnologies | Antibody directed against anthrax toxins and its uses |
GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
US20210138076A2 (en) | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
ES2877356T3 (es) * | 2014-01-27 | 2021-11-16 | Molecular Templates Inc | Epítopo de MHC de clase I que suministra polipéptidos |
US20160177284A1 (en) | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
ES2723774T3 (es) | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
SI3604333T1 (sl) | 2014-03-11 | 2021-08-31 | Molecular Templates, Inc. | Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38 |
WO2015136947A1 (en) | 2014-03-14 | 2015-09-17 | Raqualia Pharma Inc. | Azaspiro derivatives as trpm8 antagonists |
CN106604934A (zh) | 2014-06-11 | 2017-04-26 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
KR102451080B1 (ko) | 2014-06-12 | 2022-10-06 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 효소적 방법을 통한 균일한 항체 약물 접합체 |
US10550197B2 (en) | 2014-06-18 | 2020-02-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | CAR-expressing NK-92 cells as cell therapeutic agents |
CN105713087B (zh) | 2014-11-12 | 2020-05-08 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒58型单克隆抗体及其应用 |
AU2016215205B2 (en) | 2015-02-05 | 2021-10-21 | Molecular Templates, Inc. | Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
KR20220018081A (ko) | 2015-03-04 | 2022-02-14 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 결합 분자 및 그의 용도 |
EP3660035A1 (en) | 2015-05-30 | 2020-06-03 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
KR20180030085A (ko) | 2015-07-26 | 2018-03-21 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
WO2017172518A1 (en) | 2016-03-29 | 2017-10-05 | Stcube, Inc. | Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
RU2770590C2 (ru) | 2016-10-30 | 2022-04-18 | Шанхай Хенлиус Байотек, Инк. | Антитела против pd-l1 и их варианты |
KR102580647B1 (ko) | 2016-12-07 | 2023-09-20 | 몰레큘러 템플레이츠, 인코퍼레이션. | 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자 |
WO2018124642A2 (ko) | 2016-12-26 | 2018-07-05 | 단국대학교 천안캠퍼스 산학협력단 | 치수줄기세포의 상아 모전구세포로의 분화용 조성물 및 상아모전구세포 표면에 특이적으로 결합하는 IgG 또는 IgM 타입 단일 클론 항체 |
CN110536695B (zh) | 2017-01-25 | 2024-05-10 | 分子模板公司 | 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子 |
US20200190138A1 (en) | 2017-02-28 | 2020-06-18 | Chugai Seiyaku Kabushiki Kaisha | Protein purification with protein l |
AU2018231618A1 (en) | 2017-03-09 | 2019-10-03 | Genmab A/S | Antibodies against PD-L1 |
JP7159151B2 (ja) | 2017-09-25 | 2022-10-24 | Jsr株式会社 | イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
WO2020154531A1 (en) * | 2019-01-23 | 2020-07-30 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
AU2020348861A1 (en) | 2019-09-18 | 2022-01-27 | Molecular Templates, Inc. | PD-L1 binding molecules comprising Shiga toxin A Subunit scaffolds |
-
2015
- 2015-01-26 ES ES15704427T patent/ES2877356T3/es active Active
- 2015-01-26 US US15/114,474 patent/US20160347798A1/en not_active Abandoned
- 2015-01-26 CN CN202010812476.0A patent/CN111909278B/zh active Active
- 2015-01-26 JP JP2016546493A patent/JP6646584B2/ja active Active
- 2015-01-26 IL IL302552A patent/IL302552B1/en unknown
- 2015-01-26 CN CN201580013355.7A patent/CN106103489B/zh active Active
- 2015-01-26 KR KR1020237005041A patent/KR20230028808A/ko not_active Application Discontinuation
- 2015-01-26 ES ES15704153T patent/ES2749862T3/es active Active
- 2015-01-26 JP JP2016546476A patent/JP6655017B2/ja active Active
- 2015-01-26 IL IL294746A patent/IL294746B2/en unknown
- 2015-01-26 KR KR1020167022292A patent/KR20160111951A/ko not_active Application Discontinuation
- 2015-01-26 AU AU2015209065A patent/AU2015209065C1/en active Active
- 2015-01-26 KR KR1020237010012A patent/KR20230048153A/ko not_active Application Discontinuation
- 2015-01-26 US US15/114,487 patent/US20160340394A1/en not_active Abandoned
- 2015-01-26 MX MX2016009807A patent/MX2016009807A/es unknown
- 2015-01-26 CN CN201580015672.2A patent/CN106414483A/zh active Pending
- 2015-01-26 IL IL287490A patent/IL287490B/en unknown
- 2015-01-26 WO PCT/US2015/012968 patent/WO2015113005A1/en active Application Filing
- 2015-01-26 KR KR1020227001124A patent/KR102514910B1/ko active IP Right Grant
- 2015-01-26 CN CN202110072027.1A patent/CN112851769A/zh active Pending
- 2015-01-26 EP EP15704153.4A patent/EP3099705B1/en active Active
- 2015-01-26 CA CA2937407A patent/CA2937407A1/en active Pending
- 2015-01-26 KR KR1020227001129A patent/KR102500408B1/ko active IP Right Grant
- 2015-01-26 EP EP15704427.2A patent/EP3099704B1/en active Active
- 2015-01-26 EP EP19173105.8A patent/EP3575312A1/en active Pending
- 2015-01-26 KR KR1020167022316A patent/KR20160113158A/ko not_active IP Right Cessation
- 2015-01-26 EP EP21155849.9A patent/EP3868776A1/en active Pending
- 2015-01-26 CA CA2937395A patent/CA2937395A1/en active Pending
- 2015-01-26 IL IL285403A patent/IL285403B2/en unknown
- 2015-01-26 WO PCT/US2015/012970 patent/WO2015113007A1/en active Application Filing
- 2015-01-26 MX MX2016009809A patent/MX2016009809A/es unknown
- 2015-01-26 AU AU2015209063A patent/AU2015209063C1/en active Active
-
2016
- 2016-07-06 IL IL246632A patent/IL246632B/en active IP Right Grant
- 2016-07-11 IL IL246701A patent/IL246701B/en active IP Right Grant
- 2016-07-27 MX MX2022010376A patent/MX2022010376A/es unknown
- 2016-07-27 MX MX2021005131A patent/MX2021005131A/es unknown
- 2016-12-14 HK HK16114241A patent/HK1226083A1/zh unknown
- 2016-12-14 HK HK16114235A patent/HK1226082A1/zh unknown
-
2018
- 2018-12-14 US US16/220,468 patent/US20190153044A1/en not_active Abandoned
-
2019
- 2019-06-21 AU AU2019204364A patent/AU2019204364C1/en active Active
- 2019-08-02 AU AU2019210656A patent/AU2019210656C1/en active Active
-
2020
- 2020-01-10 JP JP2020002993A patent/JP2020073569A/ja active Pending
- 2020-01-31 JP JP2020014954A patent/JP2020079267A/ja active Pending
- 2020-03-03 IL IL273035A patent/IL273035B/en unknown
- 2020-11-09 IL IL278586A patent/IL278586B/en unknown
- 2020-12-22 AU AU2020294212A patent/AU2020294212B2/en active Active
-
2021
- 2021-01-21 AU AU2021200390A patent/AU2021200390C1/en active Active
- 2021-04-15 US US17/231,526 patent/US11312751B2/en active Active
- 2021-06-01 JP JP2021092504A patent/JP7229570B2/ja active Active
- 2021-06-11 US US17/345,576 patent/US20220275030A1/en active Pending
- 2021-06-21 JP JP2021102325A patent/JP7126729B2/ja active Active
-
2022
- 2022-03-28 US US17/705,619 patent/US20220306701A1/en active Pending
- 2022-08-09 JP JP2022127059A patent/JP7402556B2/ja active Active
- 2022-10-17 AU AU2022256081A patent/AU2022256081B2/en active Active
- 2022-12-15 AU AU2022287636A patent/AU2022287636B2/en active Active
-
2023
- 2023-02-07 JP JP2023016832A patent/JP7442879B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022166140A5 (ja) | ||
JP2022058385A5 (ja) | ||
KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
CN109485734B (zh) | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 | |
JP2020513779A5 (ja) | ||
JP2021508458A (ja) | Ror1特異性抗原結合分子 | |
JP2020527939A (ja) | タンパク質性ヘテロ二量体及びその用途 | |
US20100297664A1 (en) | Paratope and epitope of anti-mortalin antibody | |
WO2014060365A1 (en) | Bispecific her2 ligands for cancer therapy | |
WO2023020537A1 (zh) | 一种双特异性抗体及其用途 | |
JP2006523086A (ja) | 発癌性形態のrasに対する細胞内発現抗体 | |
KR20220161362A (ko) | 다중특이적 항체를 작제하기 위한 플랫폼 | |
CN113004415B (zh) | 靶向her2和4-1bb的双特异性抗体及其应用 | |
KR101963230B1 (ko) | 복수개의 단일 항체를 포함하는 단백질 복합체 | |
CN113480657B (zh) | 针对her2的单域抗体及其衍生蛋白和应用 | |
JPWO2022224997A5 (ja) | ||
CN108290942B (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
CN112661844B (zh) | 一种靶向EGFRvIII的单链抗体及应用 | |
CN107698681A (zh) | 一种识别hla‑a2/rmfpnapyl的单域抗体 | |
JP6886474B2 (ja) | ヒト及びマウスSema3Aに交差結合する抗体及びその用途 | |
JP2017014112A (ja) | 抗サバイビン抗体又は抗体誘導体及びそれらの利用 | |
CN108484781B (zh) | 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用 | |
CN114369163B (zh) | 与人血小板衍生生长因子受体β结合的羊驼源纳米抗体 | |
CN112166196A (zh) | 大核酸的靶向细胞内递送 | |
EP3150637A1 (en) | Multispecific antibodies |